Abstract
Clinical preparations of bleomycins (BM) were tested for their recombinogenicity and mutagenicity at relatively high survival levels in the simple eucaryote, Saccharomyces cerevisiae. More than a dozen test loci or genetic intervals were assayed for bleomycin-induced mutation or recombination. Treatments of stationary phase diploid yeast routinely resulted in 25–75% inactivation. The antibiotic was mildly to very highly recombinogenic and mutagenic, with one exception. The amount of bleomycin-induced mutation, gene conversion or crossing-over depended upon the particular genetic markers assayed. The drug was also potently recombinogenic in yeast cells growing in the presence of BM. These results contrast with the finding that this antitumor agent was not mutagenic in the Salmonella/mammalian microsome mutagenicity test; possible explanations of this difference are given.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
